Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of inflammation, respiratory tract infections and cystic fibrosis

A technology for cystic fibrosis and inflammation, applied in the direction of respirators, respiratory diseases, inorganic active ingredients, etc., can solve problems such as reduced life expectancy

Inactive Publication Date: 2017-09-26
ADVANCED INHILATION THERAPIES AIT LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This results in reduced life expectancy in human subjects diagnosed with or suffering from CF due to excessive lung tissue destruction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of inflammation, respiratory tract infections and cystic fibrosis
  • Treatment of inflammation, respiratory tract infections and cystic fibrosis
  • Treatment of inflammation, respiratory tract infections and cystic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0480] Inhalation of nitric oxide in human subjects diagnosed with or suffering from CF

[0481] The open-label phase II clinical study of the present disclosure presented herein examined some aspects of the use of NO as an adjuvant therapy for CF. Chronic microbial lung infection, particularly Pseudomonas aeruginosa, is a major cause of morbidity and mortality in human subjects diagnosed with or suffering from CF. The aim of the following study was to evaluate the safety and tolerability of NO inhalation in human subjects diagnosed with or suffering from CF.

[0482] Symptoms of CF:

[0483]In some human subjects diagnosed with or suffering from CF, symptoms are observed in infancy, but other CF patients may not develop symptoms until adolescence or adulthood. Fifty percent of human subjects diagnosed with CF have pulmonary manifestations that usually begin in infancy. Adolescents may experience delayed growth and development, delayed puberty, and decreased exercise tolera...

Embodiment 2

[0510] Nitric Oxide Inhalation for Inflammation

[0511] A cohort of human subjects diagnosed with inflammation was treated by intermittent inhalation of nitric oxide according to the protocol given in Example 1 above, i.e. inhalation of 160 ppm nitric oxide for 30 minutes, 3 times a day, 5 consecutive days a week for 2 Weekly, with at least 3.5 hours between inhalations.

[0512] Inflammatory biomarkers in blood / serum:

[0513]Blood / serum levels of inflammatory biomarkers such as CRP, TNFα, IL-1β, IL-6, IL-8, IL-10, and IL-12p70 were determined using blood draws and analytical procedures before, after, and throughout treatment .

[0514] R&D Systems' Human Ferrofluid Screening Test is an exemplary analytical procedure. It is a flexible microsphere-based multiple Platform that allows simultaneous screening of up to 100 user-defined analytes of interest using cell culture supernatant, serum, or plasma samples in polystyrene bead format and up to 50 analytes in magnetic bea...

Embodiment 3

[0521] Nitric Oxide Inhalation for Bronchiolitis

[0522] in accordance with the following and Figure 5 The method outlined in intermittent nitric oxide inhalation to treat a cohort of human subjects diagnosed with acute bronchiolitis.

[0523] Subjects were screened within 4 hours of entering the Department of Pediatrics. To be included in the study, subjects needed to be 2 to 12 months old, diagnosed with acute bronchiolitis, and have a clinical score of 10 or less (see Table 2).

[0524] Subjects diagnosed with concomitant diseases such as pneumonia, urinary tract infection, or otitis media; methemoglobinemia; chronic lung disease; immunodeficiency; or heart disease (including congenital heart disease) were excluded from the study. Subjects with underlying genetic disease (CF, Down syndrome) or chronic lung disease (bronchopulmonary dysplasia, primary ciliary dyskinesia, bronchiolitis obliterans) or hypotension were also excluded. Other major exclusion criteria were as ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treating a disease in a human subject in need thereof, wherein the disease is selected from the group consisting of inflammation, bronchiolitis and cystic fibrosis. The method comprises repeatedly administering to the human subject a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the level of at least one inflammatory biomarker in the human subject when compared to the level of the inflammatory biomarker prior to the administration; b) reduce the microbial density by 1 to 2 log units as measured by colony forming units in the human subject when compared to the microbial density prior to the administration; or c) a combination thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 041,258, filed August 25, 2014, and U.S. Provisional Patent Application No. 62 / 041,272, filed August 25, 2014, the contents of which are incorporated herein by reference in their entirety . technical field [0003] The present invention in some embodiments thereof relates to therapy, more particularly but not exclusively to methods and devices for treating inflammation, respiratory infection or cystic fibrosis in a human subject. Background technique [0004] Inflammation is part of the complex biological response of vascular tissue to noxious stimuli such as pathogens, damaged cells or irritants. Typical symptoms of acute inflammation are pain, heat, warmth, redness, swelling, and loss of function. [0005] Respiratory tract infections (RTIs) are a leading cause of hospitalization, economic burden, mortality and morbidity worldwide. In ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/00A61M16/10A61M16/12
CPCA61K33/00A61P11/00A61P31/04A61P31/12Y02A50/30G01N33/84G01N2800/52
Inventor Y·阿-盖伊D·格林伯格R·威兹曼
Owner ADVANCED INHILATION THERAPIES AIT LTD